ABSTRACT
Objective:To investigate the expressions of human epidermal growth factor receptor 2 (HER2) in recurrent patients after radical gastrectomy and its correlation with clinicopathologic features and prognosis.Methods:The clinical data of 116 recurrent patients after radical gastrectomy between December 2011 and March 2019 in Fujian Cancer Hospital were retrospectively analyzed. The relationship between HER2 expression of the tissues after radical gastrectomy and clinicopathological features as well as prognosis was also analyzed.Results:HER2 positive rate was 19.8% (23/116) in gastric cancer specimens of 116 patients after radical gastrectomy. HER2 positive rate in highly and moderately differentiated patients with gastric cancer was higher than that in those with poorly differentiated gastric cancer [33.3% (11/33) vs. 14.5% (12/83), χ2 = 5.292, P < 0.05]. HER2 positive rate in patients with lung metastasis was higher than that in patients without lung metastasis [42.1% (8/19) vs. 15.5% (15/97), χ2 = 5.517, P < 0.05]. There were no statistical differences in HER2 positive rate among gastric cancer patients with different gender, age, tumor location, recurrent site, TNM stage, number of metastasis, neurovascular invasion, liver metastasis, local recurrence (all P > 0.05). HER2 expression was not associated with disease-free survival time ( P > 0.05). Conclusion:HER2 expression is associated with the differentiation degree of gastric cancer and the location of distant metastasis, but it can not be used as a predictor for recurrence of gastric cancer.